Intravascular hemolysis, vascular endothelial cell activation and thrombophilia in splenectomized patients with hemoglobin E/β-thalassemia disease

Acta Haematologica

Volumn 132, Issue 1, 2014, Pages 100-107

  Atichartakarn, Vichai ^a   Chuncharunee, Suporn ^a   Archararit, Napaporn ^a   Udomsubpayakul, Umaporn ^a   Aryurachai, Katcharin ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Hemolysis; Splenectomy; Thalassemia; Thrombophilia

Indexed keywords

AMINOTRANSFERASE; BILIRUBIN GLUCURONIDE; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FERRITIN; HEMOGLOBIN E; LACTATE DEHYDROGENASE; PADGEM PROTEIN; THROMBIN ANTITHROMBIN COMPLEX; VASCULAR CELL ADHESION MOLECULE 1;

ADOLESCENT; ADULT; AGED; ARTICLE; ASPLENIA; BETA THALASSEMIA; BIOLOGICAL ACTIVITY; BLOOD CELL COUNT; BLOOD CHEMISTRY; BLOOD LEVEL; CELL ACTIVATION; CLINICAL EVALUATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HEMOLYTIC ANEMIA; HUMAN; INFLAMMATION; INTRAVASCULAR HEMOLYSIS; IRON OVERLOAD; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; SPLENECTOMY; THROMBOPHILIA; CLINICAL TRIAL; DISEASE MARKER; THROMBOCYTE; VASCULAR ENDOTHELIUM;

ADULT; ANTITHROMBIN III; BETA-THALASSEMIA; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; E-SELECTIN; ENDOTHELIAL CELLS; FEMALE; HEMOGLOBIN E; HEMOLYSIS; HUMANS; MALE; MIDDLE AGED; P-SELECTIN; PEPTIDE HYDROLASES; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; SPLENECTOMY; THROMBOPHILIA; VASCULAR CELL ADHESION MOLECULE-1; YOUNG ADULT;

EID: 84893677885     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000355719     Document Type: Article

References (45)

1. Borgna-Pignatti C, Galanello R: Thalassemias and related disorders: quantitative disorders of hemoglobin synthesis; in Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B, Arber DA, Means RT Jr (eds): Wintrobe's Clinical Hematology, ed 12. Philadelphia, Lippincott Williams and Wilkins, 2009, pp 1083-1131.
2. Fucharoen S, Winichagoon P: Clinical and hematologic aspects of hemoglobin E/α-thalassemia. Curr Opin Hematol 2000; 7: 106-112.
3. Sumaraju V, Smith LG, Smith SM: Infectious complications in asplenic hosts. Infect Dis Clin North Am 2001; 15: 551-565.
4. Kyaw MH, Holmes EM, Toolis F, Wayne B, Chalmers J, Jones IG, Campbell H: Evaluation of severe infection and survival after splenectomy. Am J Med 2006; 119: 276.e1-276.e7.
5. Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli G, Mannucci PM: Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol 2000; 111: 467-473.
6. Eldor A, Rachmilewitz EA: The hypercoagulable state in thalassemia. Blood 2002; 99: 36-43.
7. Banyatsuppasin W, Butthep P, Atichartakarn V, Thakkinstian A, Archararit N, Pattanapanyasat K, Chuncharunee S: Activation of mononuclear phagocytes and its relationship to asplenia and phosphatidylserine exposing red blood cells in hemoglobin E/α-thalassemia patients. Am J Hematol 2011; 86: 89-92.
8. Closse C, Dachary-Prigent J, Boisseau MR: Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium. Br J Haematol 1999; 107: 300-302.
9. Ruf A, Pick M, Deutsch V, Patscheke H, Goldfarb A, Rachmilewitz EA, Guillin MC, Eldor A: In-vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with thalassaemia major. Br J Haematol 1997; 98: 51-56.
10. Atichartakarn V, Angchaisuksiri P, Aryurachai K, Onpun S, Chuncharunee S, Thakkinstian A, Atamasirikul K: Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/α-thalassaemic patients. Br J Haematol 2002; 118: 893-898.
11. Tripodi A, Cappellini MD, Chantarangkul V, Padovan L, Fasulo MR, Marcon A, Mannucci PM: Hypercoagulablility in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma. Haematologica 2009; 94: 1520-1527.
12. Atichartakarn V, Chuncharunee S, Chandanamattha P, Likittanasombat K, Aryurachai K: Correction of hypercoagulability and amelioration of pulmonary arterial hypertension by chronic blood transfusion in an asplenic hemoglobin E/α-thalassemia patient. Blood 2004; 103: 2844-2846.
13. Chuncharunee S, Atichartakarn V, Archararit N, Aryurachai K: Correction of coagulation and inflammation activation by chronic blood transfusion in an asplenic patient with haemoglobin E/α-thalassaemia and pulmonary arterial hypertension. Transfus Med 2013; 23: 276-278.
14. Sirachainan N, Thongsad J, Pakakasama S, Hongeng S, Chuansumrit A, Kadegasem P, Tirakanjana A, Archararit N, Sirireung S: Normalized coagulation markers and anticoagulation proteins in children with severe α-thalassemia disease after stem cell transplantation. Thromb Res 2012; 129: 765-770.
15. Hebbel RP, Osarogiagbon R, Kaul D: The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation 2004; 11: 129-151.
16. Rother RP, Bell L, Hillmen P, Gladwin MT: The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005; 293: 1653-1662.
17. Kato GJ, Hsieh M, Machado RF, Taylor J, Little J, Butman JA, Lehky T, Tisdale J, Gladwin MT: Cerebrovascular disease associated with sickle cell pulmonary hypertension. Am J Hematol 2006; 81: 503-510.
18. Mehari A, Alam S, Tian X, Cuttica MJ, Barnett CF, Miles G, Xu D, Seamon C, Adams-Graves P, Castro OL, Minniti CP, Sachdev V, Taylor JG 6th, Kato GJ, Machado RF: Hemodynamic predictors of mortality in adults with sickle cell disease. Am J Respir Crit Care Med 2013; 187: 840-847.
19. Karimi M, Khanlari M, Rachmilewitz EA: Cerebrovascular accident in α-thalassemia major (α-TM) and α-thalassemia intermedia (α-TI). Am J Hematol 2008; 83: 77-79.
20. Atichartakarn V, Likittanasombat K, Chuncharunee S, Chandanamattha P, Worapongpaiboon S, Angchaisuksiri P, Aryurachai K: Pulmonary arterial hypertension in previously splenectomized patients with α-thalassemic disorders. Int J Hematol 2003; 78: 139-145.
21. Aessopos A, Farmakis D: Pulmonary hypertension in α-thalassemia. Ann NY Acad Sci 2005; 1054: 1-8.
22. Atichartakarn V, Angchaisuksiri P, Aryurachai K, Chuncharunee S, Thakkinstian A: In vivo platelet activation and hyperaggregation in hemoglobin E/α-thalassemia: a consequence of splenectomy. Int J Hematol 2003; 77: 299-303.
23. Habib A, Kunzelmann C, Shamseddeen W, Zobairi F, Freyssinet JM, Taher A: Elevated levels of circulating procoagulant microparticles in patients with α-thalassemia intermedia. Haematologica 2008; 93: 941-942.
24. Premawardhena A, Fisher CA, Olivieri NF, de Silva S, Arambepola M, Perera W, O'Donnell A, Peto TE, Viprakasit V, Merson L, Muraca G, Weatherall DJ: Haemoglobin E beta thalassaemia in Sri Lanka. Lancet 2005; 366: 1467-1470.
25. Mohandas N, Clark MR, Jacobs MS, Groner W, Shohet SB: Ektacytometric analysis of factors regulating red cell deformability. Blood Cells 1980; 6: 329-334.
26. Xu X, Zeng Z, Yao W, Sun D, Ka W, Zhou S, Wen Z: Alteration in hemorheological properties of erythrocytes in nude mice with erythroleukemia and the treatment effects of etoposide. Clin Hemorheol Microcirc 2005; 33: 347-361.
27. Garozzo G, Distefano R, Miceli A, Bonomo P: Detection of ICAM-1, ICAM-2, ICAM-3, PECAM-1 and VCAM-1, evaluation of hypercoagulable state and platelet aggregation in hemoglobinopathy patients with erythroblasts. Haematologica 2001; 86: 778-779.
28. Reinhart WH, Chien S: Red cell vacuoles: their size and distribution under normal conditions and after splenectomy. Am J Hematol 1988; 27: 265-271.
29. Westerman M, Pizzey A, Hirschman J, Cerino M, Weil-Weiner Y, Ramotar P, Eze A, Lawrie A, Purdy G, Mackie I, Porter J: Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. Br J Haematol 2008; 142: 126-135.
30. Fibach E, Rachmilewitz E: The role of oxidative stress in hemolytic anemia. Curr Mol Med 2008; 8: 609-619.
31. Basu S, Banerjee D, Chandra S, Chakrabarti A: Loss of phospholipid membrane asymmetry and sialylated glycoconjugates from erythrocyte surface in haemoglobin E/α-thalassaemia. Br J Haematol 2008; 141: 92-99.
32. Kato GJ, McGowan V, Machado RF, Little JA, Taylor J VI, Morris CR, Nichols JS, Wang X, Poljakovic M, Morris SM Jr, Gladwin MT: Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006; 107: 2279-2285.
33. Rivella S: Ineffective erythropoiesis and thalassemias. Curr Opin Hematol 2009; 16: 187-194.
34. Morris CR, Kuypers FA, Kato GJ, Lavrisha L, Larkin S, Singer T, Vichinsky EP: Hemolysis-associated pulmonary hypertension in thalassemia. Ann NY Acad Sci 2005; 1054: 481-485.
35. Setty BNY, Rao AK, Stuart MJ: Thrombophilia in sickle cell disease: the red cell connection. Blood 2001; 98: 3228-3233.
36. Setty BNY, Betal SG, Zhang J, Stuart MJ: Heme induces endothelial tissue factor expression: potential role in hemostatic activation in patients with hemolytic anemia. J Thromb Haemost 2008; 6: 2202-2209.
37. Setty BNY, Stuart MJ, Dampier C, Brodecki D, Allen JL: Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology. Lancet 2003; 362: 1450-1455.
38. Haraldsen G, Kvale D, Lien B, Farstad IN, Brandtzaeg P: Cytokine-regulated expression of E-selectin, intercellular adhesion molecule-1, and vascular adhesion molecule in human microvascular endothelial cells. J Immunol 1996; 156: 2558-2565.
39. Esmon CT: The interactions between inflammation and coagulation. Br J Haematol 2005; 131: 417-430.
40. Aydinok Y, Bayraktaroglu S, Yildiz D, Alper H: Myocardial iron loading in patients with thalassemia major in Turkey and the potential role of splenectomy in myocardial siderosis. J Pediatr Hematol Oncol 2011; 33: 374-378.
41. Aggeli C, Antoniades C, Cosma C, Chrysohoou C, Tousoulis D, Ladis V, Karageorga M, Pitsavos C, Stefanadis C: Endothelial dysfunction and inflammatory process in transfusion-dependent patients with α-thalassemia major. Int J Cardiol 2005; 105: 80-84.
42. Walter PB, Macklin EA, Porter J, Evans P, Kwiatkowski JL, Neufeld EJ, Coates T, Giardina PJ, Vichinsky E, Olivieri N, Alberti D, Holland J, Harmatz P, for the Thalassemia Clinical Research Network: Inflammation and oxidant-stress in α-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica 2008; 93: 817-825.
43. Conran N, Costa FF: Hemoglobin disorders and endothelial cell interactions. Clin Biochem 2009; 42: 1824-1838.
44. Archararit N, Chuncharunee S, Pornvoranunt A, Atamasirikul K, Rachakom B, Atichartakarn V: Serum C-reactive protein level in postsplenectomized thalassemic patients. J Med Assoc Thai 2000; 83(suppl 1):S63-S69.
45. Angchaisuksiri P, Atichartakarn V, Aryurachai K, Archararit N, Chuncharunee S, Tiraganjana A, Rattanasiri S: Hemostatic and thrombotic markers in patients with hemoglobin E/α-thalassemia disease. Am J Hematol 2007; 82: 1001-1004.